Figure 2.
Number of patient cohorts (N), median overall survival (mOS), and survival gain (SG) analysis for therapy with topotecan (TPT), irinotecan (CPT-11), etoposide (VP-16), and teniposide (VM-26). a: Outcome data after analysis on the entire database regarding number of cohorts, mOS, and SG in months for treatment regimens with each topoisomerase inhibitor. Survival gain analysis for b: CTP-11 and c: VP-16 calculated from the entire database inclusive of all treatment regimens (0), regimens using individual topoisomerase inhibitors (yes), regimens not using topoisomerase inhibitors (no), and regimens where data regarding topoisomerase inhibitors was not included upon entry in the database (unknown). The difference between predicted outcome and observed outcome for each cohort was defined as ‘survival gain’ indicating success or failure of treatment, as previously described (20).